Results for: Amyotrophic Lateral Sclerosis

NeuroSense Therapeutics is in advanced discussions with major pharmaceutical companies for a potential partnership to develop and commercialize its ALS drug candidate, PrimeC. The company anticipates receiving terms for the partnership in the fourth quarter of 2024, based on promising Phase 2b trial data showing PrimeC’s efficacy in mitigating ALS progression and improving survival rates.

Scientists have identified a gene mutation linked to the rare recovery of ALS patients, offering a potential new avenue for treatment. The mutation in the IGFBP7 gene enhances the activity of IGF-1, a protein that protects motor neurons. While more research is needed, this finding could lead to new therapies for ALS.